Abstract
Novel approaches to vaccine development include structure-based immunogen design, gene-based vaccine platforms and formulation of recombinant antigens with potent adjuvants. These technologies are producing encouraging results in the development of vaccines for globally important diseases such as tuberculosis, influenza and respiratory syncytial virus. Here we highlight the most important developments in these areas over the past 18 months.
MeSH terms
-
Adjuvants, Immunologic / therapeutic use*
-
BCG Vaccine / therapeutic use
-
Drug Development
-
Humans
-
Influenza Vaccines / immunology
-
Influenza Vaccines / therapeutic use*
-
Influenza, Human / prevention & control*
-
Latent Tuberculosis / drug therapy*
-
RNA, Messenger / immunology
-
Recombinant Proteins
-
Respiratory Syncytial Virus Infections / prevention & control*
-
Respiratory Syncytial Virus Vaccines / immunology
-
Respiratory Syncytial Virus Vaccines / therapeutic use*
-
Respiratory Syncytial Virus, Human / immunology
-
Tuberculosis Vaccines / immunology
-
Tuberculosis Vaccines / therapeutic use*
-
Vaccines / immunology
-
Vaccines / therapeutic use
-
Vaccines, Synthetic
-
Viral Fusion Proteins / immunology
Substances
-
Adjuvants, Immunologic
-
BCG Vaccine
-
Influenza Vaccines
-
RNA, Messenger
-
Recombinant Proteins
-
Respiratory Syncytial Virus Vaccines
-
Tuberculosis Vaccines
-
Vaccines
-
Vaccines, Synthetic
-
Viral Fusion Proteins